Research Topics
| Francesco RecchiaSummaryCountry: Italy Publications
| Collaborators
|
Detail Information
Publications
Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancerFrancesco Recchia
Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Avezzano, Italy
Cancer Immunol Immunother 56:699-708. 2007..Secondary endpoint was the evaluation of toxicity, progression-free survival (PFS), and overall survival (OS)...- Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinomaFrancesco Recchia
Ospedale Civile di Avezzano, Unita Operativa di Oncologia, Monterotondo, Roma
J Immunother 30:448-54. 2007..Six cycles of biochemotherapy, being followed by maintenance immunotherapy is well-tolerated and shows significant activity in patients with MRCC... 
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRCFrancesco Di Costanzo
Unit of Medical Oncology, Azienda Ospedaliero Universitaria Careggi, Viale Pieraccini 17, 50139 Florence, Italy
J Natl Cancer Inst 100:388-98. 2008..Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor...- Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin‑eluting beads compared with lipiodolFrancesco Recchia
Department of Oncology, Civilian Hospital, Avezzano, Italy
Oncol Rep 27:1377-83. 2012..001) in DEB-TACE-treated patients compared to TACE-treated patients. DEB-TACE with doxorubicin-loaded DC Beads, a safe and reliable treatment for HCC, leads to decreased toxicity compared to TACE... - A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancerFrancesco Recchia
Unita Operativa di Oncologia, Ospedale Civile di Avezzano, AQ, Italy
Gynecol Oncol 106:164-9. 2007..This phase II study investigated the safety and activity of PLD and LOHP used in combination to treat ROC... - Liposomal pegylated doxorubicin and oxaliplatin as salvage chemotherapy in patients with metastatic gastric cancer treated earlierFrancesco Recchia
Ospedale Civile di Avezzano, Unita Operativa di Oncologia, Italy
Anticancer Drugs 21:559-64. 2010..PLD and LOHP is an active regimen, able to give palliation in a substantial percentage of MCG patients who have been pretreated with taxanes... - Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanomaFrancesco Recchia
ALS 1 Civilian Hospital, Avezzano, Oncology Division, Monterotondo, Roma
Anticancer Drugs 19:201-7. 2008..A regimen of six cycles of biochemotherapy followed by maintenance immunotherapy is well tolerated, and shows significant activity in patients with MM... - Prolonged disease control after myeloablative chemotherapy, autologous transplantation and immunotherapy in high-risk early breast cancerFrancesco Recchia
Via Del Castagneto n 15, 67056 Luco dei Marsi AQ, Italy
Anticancer Res 30:209-15. 2010.... - Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neckFrancesco Recchia
Divisione di Oncologia, ALS 1 Ospedale Civile di Avezzano, Roma, Italy
J Immunother 31:413-9. 2008..Longitudinal changes in lymphocytes, natural killer cells, and VEGF might be useful biomarkers for response and survival... - Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancerFrancesco Recchia
Ospedale Civile di Avezzano, Unita Operativa di Oncologia, Rome, Italy
Am J Clin Oncol 31:323-8. 2008.... - Maintenance immunotherapy in metastatic breast cancerFrancesco Recchia
Ospedale Civile di Avezzano, Unita Operativa di Oncologia
Oncol Rep 20:1173-9. 2008..A randomized trial is warranted... - Beta-interferon, retinoids and tamoxifen in metastatic breast cancer: long-term follow-up of a phase II studyFrancesco Recchia
Oncologia, Ospedale Civile di Avezzano, 67051 Avezzano, AQ, Italy
Oncol Rep 21:1011-6. 2009..9 months, respectively. In conclusion, the study shows that long-term treatment with TAM, beta-IFN and R in MBC is feasible, has moderate toxicity and seems to give a long-term benefit, irrespective of the receptorial status... - Immunotherapy in patients with less than complete response to chemotherapyFrancesco Recchia
Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Italy
Anticancer Res 29:567-72. 2009..Secondary endpoints were objective response, relapse-free survival (RFS), and overall survival (OS)... - Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II studyFrancesco Recchia
Ospedale Civile di Avezzano, Unita Operativa di Oncologia, Italy
Gynecol Oncol 116:202-7. 2010..Here, we report long term follow-up of a group of patients with platinum-sensitive AOC who were treated with IL-2 and RA... - Chemoimmunotherapy in the treatment of metastatic gastric cancerFrancesco Recchia
Civilian Hospital, Oncology Unit, Avezzano, Carlo Ferri Foundation, Monterotondo, Rome, and Clinical Epidemiology, University of L Aquila, Italy
Anticancer Drugs 18:597-604. 2007.... - Dose-finding study of docetaxel added to ifosfamide and cisplatin followed by concomitant capecitabine and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neckFrancesco Recchia
ALS 1 Ospedale Civile di Avezzano, Divisione di Oncologia, Monterotondo, Roma, Italy
Anticancer Res 26:2317-24. 2006.... - Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapyFrancesco Recchia
Civilian Hospital, Oncology Department, Avezzano, Italy
Anticancer Res 31:671-6. 2011..The role of adjuvant chemotherapy (CT) and hormonal therapy have not yet been established in these patients... - Oxaliplatin fractionated over two days with bimonthly leucovorin and 5-fluorouracil in metastatic colorectal cancerFrancesco Recchia
Unita operative di Oncologia, Ospedale Civile di Avezzano, Italy
Anticancer Res 24:1935-40. 2004..To evaluate the efficacy and safety of oxaliplatin (L-OHP) fractionated over two days with bimonthly 5-fluorouracil (5-FU) and leucovorin (LV), as first-line treatment of metastatic colorectal cancer (MCC) patients... - Paclitaxel plus gemcitabine in advanced non-small cell lung cancer patients with low performance statusFrancesco Recchia
Ospedale Civile di Avezzano, Monterotondo Roma, Italy
Anticancer Res 25:409-14. 2005..The aim was to determine the efficacy and safety of a platinum-free regimen combining gemcitabine and paclitaxel for the treatment of patients with advanced non-small cell lung cancer (NSCLC) and a low performance status (PS)... - Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapyFrancesco Recchia
Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Italy
Anticancer Res 25:3149-57. 2005..The aim of this phase II randomized study was to verify the role of RA in this drug combination... - Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancerFrancesco Recchia
Ospedale Civile di Avezzano, Unita Operativa di Oncologia, Rome, Italy
Int J Oncol 27:1039-46. 2005..These preliminary data show that, after chemotherapy for AOC, the administration of low-dose subcutaneous IL-2 and oral RA is feasible, has low toxicity, is cost-effective and improves both PFS and OS... - Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancerFrancesco Recchia
Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Avezzano, Italy
J Immunother 29:87-94. 2006.... - Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinomaFrancesco Recchia
Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Avezzano, Italy
Cancer 106:514-23. 2006.... - Cardiac metastases in malignant fibrous histiocytoma. A case reportFrancesco Recchia
Unita Operativa di Oncologia, Ospedale Civile di Avezzano, AQ, Italy
Tumori 92:76-8. 2006..The response continued to improve with immunotherapy. The patient returned to normal physical activity. He died four years later due to a ventricular arrhythmia... - Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II studyFrancesco Recchia
Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Avezzano, Italy
Pancreas 38:e163-8. 2009..The antitumor activity and toxicity of a multi-step treatment were evaluated in patients with locally advanced, inoperable, or incompletely resected pancreatic (Pa) and biliary tree (Bt) adenocarcinomas (ADKs)... - Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancerFrancesco Recchia
ALS 2 Ospedale Civile di Avezzano, Division of Oncology, Monterotondo, Roma, Italy
Anticancer Drugs 14:633-8. 2003..Promising anti-tumor activity was observed... - Gemcitabine, ifosfamide and vinorelbine in advanced non-small cell lung cancer: a phase II studyFrancesco Recchia
Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Universita degli Studi di L Aquila, Italy
Anticancer Res 22:1321-8. 2002..The objective of this phase II study was to determine the activity and toxicity of gemcitabine, ifosfamide and vinorelbine, in the treatment of patients with advanced non-small cell lung cancer (NSCLC)... - Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot studyFrancesco Recchia
Ospedale Civile di Avezzano, Divisione di Oncologia, Fondazione Carlo Ferri, Monterotondo, Roma, Italy
Anticancer Drugs 13:417-24. 2002..No unexpected adverse events were reported. These data show that the addition of goserelin to adjuvant therapy of premenopausal patients with early breast cancer is well tolerated and protects long-term ovarian function... - Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: a phase II studyFrancesco Recchia
Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Italy
Int J Oncol 20:1275-82. 2002..A sustained increase in the immunological parameters known to be prognostically relevant was observed and a clear benefit on tumor response from immunotherapy was obtained in 7.5% of patients... 
Triple-negative breast cancer: multipronged approach, single-arm pilot phase II studyFrancesco Recchia
Oncology Unit, Civilian Hospital Avezzano, Italy Carlo Ferri Foundation Monterotondo, Rome, Italy
Cancer Med 1:89-95. 2012..Induction chemotherapy, followed by chemoradiation therapy and HDCT, provides a prolonged disease-free period and a significant increase in overall survival in TNBC, with an acceptable toxicity profile...- Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective surveyLazzaro Repetto
Oncology Department, Istituto Nazionale di Riposo e Cura per Anziani, INRCA IRCCS, Via Cassia 1167, Rome 00189, Italy
Crit Rev Oncol Hematol 72:170-9. 2009..To evaluate the frequency of chemotherapy-induced myelotoxicity in cancer patients, the related treatment (G-CSF, rHuEPO), and the occurrence of chemotherapy dose reductions, delays or discontinuations... - High-dose carboplatin, cyclophosphamide, etoposide with hematological growth factors, without stem cell support in patients with advanced cancerFrancesco Recchia
UnitĂ operative di Oncologia Ospedale Civile di Avezzano, Italy
Anticancer Res 23:4141-7. 2003..The aim of this phase II study was to evaluate the activity and toxicity of HDCT with CB, CT and VP administered with growth factors, without PBPC in a group of patients with advanced solid tumors...